Profil
Gavin B.
Samuels is Senior Vice President of Business Development for Quark Pharmaceuticals, Inc. Prior to joining Quark Pharmaceuticals March, 2007 he held several positions at Worldwide Business Development and Worldwide Product Development Groups for Pfizer, Inc. Previously, he was Senior Associate of Healthcare Strategy and Corporate Affairs for Merck Sharpe & Dohme in Australia.
Dr. Samuels received an MS from the University of Witwatersrand, an MBA from the University of New England (Australia) and a degree in Health Economics from Monash University, Australia.
Anciens postes connus de Gavin B. Samuels
| Sociétés | Poste | Fin |
|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 23/09/2010 |
| PFIZER, INC. | Corporate Officer/Principal | - |
Formation de Gavin B. Samuels
| University of the Witwatersrand | Doctorate Degree |
| University of New England (Australia) | Masters Business Admin |
| Monash University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
